Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Recruiting 2Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 3Expanded_access 1

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 2Lymphoid 2

Conditions

Myelodysplastic Syndromes 77Leukemia, Myeloid, Acute 72Leukemia, Myelogenous, Chronic, BCR-ABL Positive 34Myeloproliferative Disorders 33Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Lymphoma, Non-Hodgkin 21Primary Myelofibrosis 18Leukemia, Myelomonocytic, Chronic 17Hodgkin Disease 15Leukemia 14Myelodysplastic-Myeloproliferative Diseases 12Polycythemia Vera 10Leukemia, Biphenotypic, Acute 10Histiocytosis, Langerhans-Cell 10Anemia, Refractory, with Excess of Blasts 10Sarcoma 9Neuroblastoma 9Multiple Myeloma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Glioma 9Wilms Tumor 8Rhabdoid Tumor 8Neuroectodermal Tumors, Primitive, Peripheral 8Medulloblastoma 8Hepatoblastoma 8Ependymoma 8Blast Crisis 8Thrombocythemia, Essential 7Rhabdomyosarcoma 7Osteosarcoma 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × Myeloid × 30 days × Clear all
NCT06915766 2026-05-28

Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

Cogent Biosciences, Inc.

Available
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT04910685 2026-05-22

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Blueprint Medicines Corporation

Phase 2/3 Recruiting
534 enrolled
Myeloid

Mastocytosis, Systemic

NCT05186753 2026-05-22

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

Cogent Biosciences, Inc.

Phase 2 Active not recruiting
237 enrolled
Myeloid

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Mastocytosis, Mastocytosis, Systemic

NCT05362773 2026-05-22

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

MacroGenics

Phase 1 Recruiting
130 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Hairy Cell, Myelodysplastic Syndromes, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡